Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Open accessThe DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Abstract
models by enabling precise control over various parameters. These parameters include the properties of the extracellular matrix, mechanical forces exerted on cells, the physico-chemical environment, cell composition, and the architecture of the tumor microenvironment. Such fine control allows ToC to closely replicate the complex microenvironment and interactions within tumors, facilitating the study of cancer progression and therapeutic responses in a highly representative manner. Importantly, by incorporating patient-derived cells or tumor xenografts, ToC models have demonstrated promising results in terms of clinical validation. We also examined the potential of ToC for pharmaceutical industries in which ToC adoption is expected to occur gradually. Looking ahead, given the high failure rate of clinical trials and the increasing emphasis on the 3Rs principles (replacement, reduction, refinement of animal experimentation), ToC models hold immense potential for cancer research. In the next decade, data generated from ToC models could potentially be employed for discovering new therapeutic targets, contributing to regulatory purposes, refining preclinical drug testing and reducing reliance on animal models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Less than a handful of ovarian cancer-based micro-fluidic chips incorporates immune cells, however, the TME plays an essential role in tumor initiation, development and therapy response (Surendran et al., 2021; Bouquerel et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Bouquerel et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–222 of 222
Davidov, T., Efraim, Y., Hayam, R., Oieni, J., Baruch, L., & Machluf, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111624 · Cited by 29
Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model
Chernyavska, M., Hermans, C. K. J. C., Chan, C., Baumann, N., Rösner, T., Leusen, J. H. W., Valerius, T., & Verdurmen, W. P. R. (2022) · Organs-on-a-Chip · doi:10.1016/j.ooc.2022.100019 · Cited by 27
Azizipour, N., Avazpour, R., Weber, M. H., Sawan, M., Ajji, A., & Rosenzweig, D. H. (2022) · Micromachines · doi:10.3390/mi13040587 · Cited by 27
Singh, D., Deosarkar, S. P., Cadogan, E. B., Flemington, V., Bray, A., Zhang, J., Reiserer, R. S., Schaffer, D. K., Gerken, G. B., Britt, C. M., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001624 · Cited by 27
Close, D. A., Wang, A. X., Kochanek, S. J., Shun, T., Eiseman, J. L., & Johnston, P. A. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218812429 · Cited by 26
Kim, Y., Ko, J., Shin, N., Park, S., Lee, B., Kim, S., Song, J., Lee, S.-J., Kang, K., Lee, J., et al. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28221 · Cited by 26
Mimicking and surpassing the xenograft model with cancer-on-chip technology
Komen, J., van Neerven, S. M., van den Berg, A., Vermeulen, L., & van der Meer, A. D. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103303 · Cited by 24
Evaluation of nanoencapsulated verteporfin’s cytotoxicity using a microfluidic system
Tokarska, K., Bułka, M., Bazylińska, U., Jastrzębska, E., Chudy, M., Dybko, A., Wilk, K. A., & Brzózka, Z. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.02.052 · Cited by 23
Precise and fast control of the dissolved oxygen level for tumor-on-chip
Bouquerel, C., César, W., Barthod, L., Arrak, S., Battistella, A., Gropplero, G., Mechta‐Grigoriou, F., Zalcman, G., Parrini, M. C., Verhulsel, M., et al. (2022) · Lab on a Chip · doi:10.1039/d2lc00696k · Cited by 22
Self-citationReal-time assessment of nanoparticle-mediated antigen delivery and cell response
Cunha-Matos, C. A., Millington, O. R., Wark, A. W., & Zagnoni, M. (2016) · Lab on a Chip · doi:10.1039/c6lc00599c · Cited by 21
Flont, M., Jastrzębska, E., & Brzózka, Z. (2020) · The Analyst · doi:10.1039/d0an00911c · Cited by 21
Veith, I., Mencattini, A., Picant, V., Serra, M., Leclerc, M., Comes, M. C., Mami‐Chouaib, F., Camonis, J., Descroix, S., Shirvani, H., et al. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008870 · Cited by 21
Self-citationTumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients
Ulukaya, E., Karakaş, D., & DIMAS, K. S. (2021) · Medicina · doi:10.3390/medicina57060636 · Cited by 20
Engineered Exosomes as a Photosensitizer Delivery Platform for Cancer Photodynamic Therapy
Dao, A., Kushwaha, R., Kumar, A., Huang, H., & Banerjee, S. (2022) · ChemMedChem · doi:10.1002/cmdc.202200119 · Cited by 20
Wu, J., Li, H., Chen, Q., Lin, X., Liu, W., & Lin, J. (2014) · RSC Advances · doi:10.1039/c4ra01665c · Cited by 19
A new drug testing platform based on 3D tri-culture in lab-on-a-chip devices
Gökçe, B., Akçok, İ., Çağır, A., & Pesen‐Okvur, D. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105542 · Cited by 17
Babu, S. P. P., Venkatabalasubramanian, S., Munisankar, S. R., & Thiyagaraj, A. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.05.007 · Cited by 11
A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts
Sablatura, L. K., Bircsak, K. M., Shepherd, P. D. A., Bathina, M., Queiroz, K. C. S., Farach‐Carson, M. C., Kittles, R. A., Constantinou, P. E., Saleh, A. D., Navone, N. M., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201434 · Cited by 11
An Integrated Microfluidics Approach for Personalized Cancer Drug Sensitivity and Resistance Assay
Desyatnik, I., Krasner, M., Frolov, L., Ronen, M., Guy, O., Wasserman, D., Tzur, A., Avrahami, D., Barbiro‐Michaely, E., & Gerber, D. (2019) · Advanced Biosystems · doi:10.1002/adbi.201900001 · Cited by 9
Azadi, S., Mohammadi, E., Tafazzoli‐Shadpour, M., & Tabatabaei, M. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.07.013 · Cited by 8
A golden era of cancer clinical trials
Webster, P. C. (2022) · Nature Medicine · doi:10.1038/s41591-022-01760-z · Cited by 7
Parsian, M., Mutlu, P., Yıldırım, E., Ildiz, C., Özen, C., & Gündüz, U. (2022) · Biomicrofluidics · doi:10.1063/5.0087532 · Cited by 5
Research works printed but not linked: 6
- T. C. Chang, A. M. Mikheev, W. Huynh, R. J. Monnat, R. C. Rostomily and A. Folch, Parallel Microfluidic Chemosensitivity Testing on Individual Slice Cultures, Lab Chip, 2014, 14(23), 4540-4551, DOI: 10.1039/b000000x/NIH. · doi:10.1039/b000000x/nih
- W. Han, S. Chen and W. Yuan, et al., Oriented collagen fibers direct tumor cell intravasation, Proc. Natl. Acad. Sci.
- M. Glicksman, Z. Li and S. Markossian, et al., In Vitro Cell Based Assays, Assay Guidance Manual, 2023. 149
- M. S. Manak, J. S. Varsanik and B. J. Hogan, et al., Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning, Nat. Biomed. Eng., 2018, 47(3), 549-562, DOI: 10.1038/s41551- 018-0285-z.Live-cell. 154 · doi:10.1038/s41551-018-0285-z.live-cell
- K. Sherkar, S. Choudante and O. Sumant, Organ-Tumor-on- a-Chip Market by Type (Lung Tumor-on-a-Chip, Bone Marrow Tumor-on-a-Chip, Brain Tumor-on-a-Chip, Breast Tumor-on-a- Chip, Urinary System Tumor-on-a-Chip, Intestine Tumor-on-a- Chip, and Liver Tumor-on-a-Chip): Global Opportunity Analysis and Industry Forecast, 2021-2030, 2021.
- D. Venturoli and B. Rippe, Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability, Am. J. Physiol. -Ren. Physiol., 2005, 288, 605-613, DOI: 10.1152/ajprenal.00171.2004.-Polydisperse. 225 · doi:10.1152/ajprenal.00171.2004.-polydisperse
Cited by
Engineering next generation vascularized organoids
Werschler, N., Quintard, C., Nguyen, S., & Penninger, J. M. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118529 · Cited by 69
Al-Kabani, A., Huda, B., Haddad, J., Yousuf, M., Bhurka, F., Ajaz, F., Patnaik, R., Jannati, S., & Banerjee, Y. (2025) · Cancers · doi:10.3390/cancers17132163 · Cited by 57
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Veith, I., Nurmik, M., Mencattini, A., Damei, I., Lansche, C., Brosseau, S., Gropplero, G., Corgnac, S., Filippi, J., Poté, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101549 · Cited by 63
Self-citationCancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 52
Sharma, P. K., & Chen, C. (2025) · Biosensors · doi:10.3390/bios15120793 · Cited by 35
Metadata
- Authors
- Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., Wilhelm, C., Zalcman, G., Parrini, M. C., & Descroix, S.
- Affiliations
- Inserm (FR)
- Institut Pierre-Gilles de Gennes pour la Microfluidique (FR)
- Pfizer (United States) (US)
- Macromolécules et Microsystèmes en Biologie et Médecine, UMR 168, Institut Curie, Institut Pierre Gilles de Gennes, 6 rue Jean Calvin, 75005, Paris, France
- Genentech (US)
- Institut Curie (FR)
- Stress and Cancer Laboratory, Inserm, U830, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France
- Corresponding author
- Descroix, Stéphanie
- ORCID
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2023
- Volume
- 23
- Issue
- 18
- Pages
- 3906-3935
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- OpenAlex
- W4385969151
- Cited by
- 58
- References
- 222
- Citations by year
- 2026: 18 · 2025: 24 · 2024: 15 · 2023: 1
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Lab on a Chip (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Funders
- Centre National de la Recherche Scientifique
- Association Nationale de la Recherche et de la Technologie
- Institut Pierre-Gilles de Gennes (ANR-10-IDEX-0001-02 PSL, ANR-10-EQPX-34, ANR-10-LABX-31)
- Fondation ARC pour la Recherche sur le Cancer (PGA12021010002992_3578)
- Institut National de la Santé et de la Recherche Médicale (19CR046-01, 53712INSERM/ITMO 20-DESCROIX 04/24)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Keywords
- tumor-on-a-chip, 3D tumor models, tumor microenvironment, patient-derived cells, tumor xenografts, clinical validation, preclinical drug testing, 3Rs, tumor progression, treatment response, extracellular matrix, mechanobiology, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Extracellular Matrix, Humans, Neoplasms, Cell Culture Techniques, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.